Treatment and survival analyses of malignant mesothelioma in Japan

References

• Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260–71.
   PubMedGoogle Scholar
• Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): A multicentre randomised trial. Lancet 2008;371:1685–94.
   PubMed Web of Science ®Google Scholar
• Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54–63, Discussion 63–5.
   PubMed Web of Science ®Google Scholar
• Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: The SEER experience. Int J Cancer 1988;41:525–30.
   PubMed Web of Science ®Google Scholar
• Gemba K, Fujimoto N, Kato K, Aoe K, Takeshima Y, Inai K, et al. National survey of malignant mesothelioma and asbestos exposure in Japan. Cancer Sci 2012;103:483–90.
   PubMed Web of Science ®Google Scholar
• Churg A, Inai K, Samet J. Tumours of the pleura. Lyon: IARC Press; 2004.
   Google Scholar
• Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108:1122–8.
   Google Scholar
• Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723–31.
   PubMed Web of Science ®Google Scholar
• Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145–52.
   PubMed Web of Science ®Google Scholar
• Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005;23: 184–9.
   PubMed Web of Science ®Google Scholar
• Treasure T, Tan C, Lang-Lazdunski L, Waller D. The MARS trial: Mesothelioma and radical surgery. Interact Cardiovasc Thorac Surg 2006;5:58–9.
   PubMedGoogle Scholar
• Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763–72.
   PubMed Web of Science ®Google Scholar
• Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathol Int 2008;58:75–83.
   PubMed Web of Science ®Google Scholar
• Walters J, Maskell NA. Biopsy techniques for the diagnosis of mesothelioma. Recent Results Cancer Res 2011;189: 45–55.
   PubMedGoogle Scholar
• Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008;60:259–63.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636–44.
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T, et al. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: A phase I/II study in Japanese patients. Jpn J Clin Oncol 2008;38:339–46.
   PubMed Web of Science ®Google Scholar